Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pazopanib + CapeOx
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
The combination **pazopanib + CapeOx** consists of oral pazopanib, a small molecule multitargeted tyrosine kinase inhibitor, plus the CapeOx chemotherapy regimen (capecitabine and oxaliplatin). **Pazopanib** inhibits angiogenesis by targeting the vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-α and PDGFR-β), and c-kit, thereby preventing tumor blood vessel formation and growth. **CapeOx** combines the antimetabolite capecitabine (an oral prodrug of 5-fluorouracil) with oxaliplatin, a platinum-based DNA crosslinker, inhibiting cell replication. This combination was investigated primarily as a first-line treatment for advanced or metastatic gastric cancer, where it demonstrated moderate anti-tumor activity and a manageable toxicity profile in phase II studies[1][2][4].
- Other names
- pazopanib plus CapeOxpazopanib plus capecitabine and oxaliplatinpazopanib/CapeOx
02
Targets
DNAPDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on pazopanib + CapeOx.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pazopanib + CapeOx.